Clinical Trial Update: A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation [Phase 2]

View source ↗

Summary

A pivotal Phase 2 study assessing HQP1351 in patients with chronic myeloid leukemia in chronic phase harboring the T315I mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• HQP1351

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Status: UNKNOWN